Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
227
¥ millions (cumulative business revenue for the first quarter)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ending June 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥227 million
Operating profit¥-61 million
Full-year earnings forecast
Business Earnings
¥838 million
Operating profit
¥-461 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Business Earnings27.2%
Operating profit--%
Number of medical institutions using Medcle19.4%
Monthly Medcle prescriptions1.4%
R&D spending16.8%
What the company explained in this material
New initiatives
- Launch a full-scale promotional campaign for Medcle independently
- Consider promotional collaborations with multiple external partners
- Launch the insomnia awareness website “A Guide to Sleep”
- Expand proposal activities based on the track record of regulatory applications using the SUSMED SourceDataSync system
Key KPIsA metric the company considers important as a management benchmark.
- Number of medical institutions using Medcle194 facilitiesAs ofEnd-October 2026
- Monthly Medcle prescriptions27 Requests/monthAs ofEnd-October 2026
- Number of development pipeline projects11 EngagementsAs ofAs of 6 November 2026
- Number of contracted projects11 Engagements
- Number of patents obtained34 Engagements
- Cumulative number of projects adopted21 Engagements
- Cumulative number of joint research collaborations24 Companies/institutions
Segment results
DTx product business
Business Earnings
¥200 million
Segment profit
¥128 million
DTx platform business
Business Earnings
¥26 million
Segment profit
¥-16 million
Market Size / Share
- Japan target market size for an insomnia treatment app¥880 100 million
- Japan potential market size for an insomnia treatment app¥3,940 100 million
- SAM for apps treating insomnia disorders420 over ¥100 million
Number of employees
51 People
As ofAs of November 2026
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending June 2027 |
| Net Sales | ¥227 million |
| Operating profit | ¥-61 million |
| Full-year earnings forecast | Business Earnings ¥838 million / Operating profit ¥-461 million |
| Progress against full-year forecast | Business Earnings 27.2% / Operating profit --% / Number of medical institutions using Medcle 19.4% / Monthly Medcle prescriptions 1.4% / R&D spending 16.8% |
| Segment results | DTx product business Business Earnings ¥200 million / Segment profit ¥128 million / DTx platform business Business Earnings ¥26 million / Segment profit ¥-16 million |
| Key KPIs | 194 facilities, 27 Requests/month, 11 Engagements, 11 Engagements, 34 Engagements, 21 Engagements, 24 Companies/institutions |
| Number of employees | 51 People |
| Market Size / Share | Japan target market size for an insomnia treatment app ¥880 100 million, Japan potential market size for an insomnia treatment app ¥3,940 100 million, SAM for apps treating insomnia disorders 420 over ¥100 million |
| New initiatives | Launch a full-scale promotional campaign for Medcle independently, Consider promotional collaborations with multiple external partners, Launch the insomnia awareness website “A Guide to Sleep”, Expand proposal activities based on the track record of regulatory applications using the SUSMED SourceDataSync system |
Items this document does not state (20)
Ordinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue included milestone revenue associated with Medcle's inclusion in insurance reimbursement coverage. The operating loss was attributable to personnel expenses, research and development expenses, head office relocation costs, promotional expenses and other factors. The DTx platform business recorded a loss due to lower revenue following the end of the system usage period for certain projects and an increase in research and development expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.